Related Experiment Video
Updated: Feb 13, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers
Tara Castellano1, Kathleen N Moore1, Laura L Holman1
1Section of Gynecologic Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Purpose:
The goal of this study was to compile a review of topics pertinent to the use of immune checkpoint inhibitors in gynecologic malignancies, including foundation for use, current agents available and trials in gynecologic cancers, special populations of interest, identification and management of toxicities, and considerations in predictive biomarkers and response assessment.
Methods:
A literature review of selected topics in reference to immune checkpoint inhibitors and gynecologic cancers was conducted on PubMed and the US Food and Drug Administration drug search application. A review of current and ongoing clinical trials was performed in clinicaltrials.gov, and selected preliminary results reported in PubMed abstracts and through the American Society of Clinical Oncologists were compiled.
Findings:
Although immunotherapy in gynecologic malignancy is relatively new, 7 agents are currently approved for use in other oncologic indications, and a multitude of trials in gynecologic cancer are ongoing. Immunotherapy has a specific set of drug toxicities that manifest and are managed unlike traditional cytotoxic therapies.
Implications:
Application of the knowledge of immune checkpoint inhibitor use in gynecologic cancers will improve care for women with cancers of the female reproductive tract. As more complex and newer immunotherapies evolve, it will be vital to accurately characterize each specific drug class and management thereof.
Insights
Immune checkpoint inhibitors offer new treatment options for gynecologic cancers. Understanding their use, toxicities, and biomarkers is crucial for improving patient care and advancing immunotherapy research.
Area of Science:
- Oncology
- Immunology
- Gynecologic Oncology
Background:
- Immune checkpoint inhibitors (ICIs) represent a novel therapeutic strategy in oncology.
- Their application in gynecologic malignancies is an evolving field with significant potential.
Purpose of the Study:
- To review the foundational knowledge, current agents, and ongoing clinical trials of ICIs in gynecologic cancers.
- To discuss special populations, toxicity management, predictive biomarkers, and response assessment for ICIs in this context.
Main Methods:
- A comprehensive literature review was performed using PubMed and the FDA drug search application.
- Current and ongoing clinical trials were identified via clinicaltrials.gov.
- Preliminary results were compiled from PubMed abstracts and ASCO reports.
Main Results:
- While immunotherapy for gynecologic malignancy is emerging, seven agents are approved for other cancers.
- Numerous clinical trials involving ICIs in gynecologic cancers are underway.
- ICI therapy presents unique toxicities distinct from traditional cytotoxic treatments.
Conclusions:
- Implementing knowledge of ICI use in gynecologic cancers can enhance care for patients with female reproductive tract cancers.
- Accurate characterization of novel immunotherapies and their management is vital as the field advances.
Related Concept Videos
02:19The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:38What is the Immune System?
01:36Humoral Immune Responses
01:23Dipeptidyl Peptidase 4 Inhibitors
02:25Overview of DNA Repair
Chemically...